Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneously primary hematopoietic neoplasm characterized by uncontrolled proliferation of immature myeloid cells, which is characterized with poor outcomes. Despite tremendous advances in the treatment paradigm of AML in the past several decades, the cure and pr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1572407/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849316136278032384 |
|---|---|
| author | Yang Liu Wanting Wang Chaofan Wang Jun Deng Yu Hu Yu Hu Heng Mei Shanshan Luo |
| author_facet | Yang Liu Wanting Wang Chaofan Wang Jun Deng Yu Hu Yu Hu Heng Mei Shanshan Luo |
| author_sort | Yang Liu |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is a heterogeneously primary hematopoietic neoplasm characterized by uncontrolled proliferation of immature myeloid cells, which is characterized with poor outcomes. Despite tremendous advances in the treatment paradigm of AML in the past several decades, the cure and prognosis remain unfavorable. More effective treatments are therefore needed to improve the clinical outcomes. Among newly emerging immunotherapies, chimeric antigen receptor (CAR)-T cell immunotherapy is an exceedingly promising approach that has remarkably improved the overall survival for patients with AML. However, current CAR-T cell therapy for AML faces numerous significant challenges such as the identification of truly AML-specific surface antigens, the on-target/off-tumor toxicity, and the immunosuppressive microenvironment of AML. In order to conquer these limitations, novel strategies to advance CAR-T therapy are urgently needed. In this comprehensive review, we summarize the current status of immunotherapy, especially CAR-T cell therapy, highlight the outcomes of current trials and the limitations of CAR-T immunotherapy, hopefully to provide novel insights into the future directions of CAR-T cells in AML. |
| format | Article |
| id | doaj-art-40fa6d7b1dd344d29225d0b5224dbf15 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-40fa6d7b1dd344d29225d0b5224dbf152025-08-20T03:51:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15724071572407Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemiaYang Liu0Wanting Wang1Chaofan Wang2Jun Deng3Yu Hu4Yu Hu5Heng Mei6Shanshan Luo7Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaAcute myeloid leukemia (AML) is a heterogeneously primary hematopoietic neoplasm characterized by uncontrolled proliferation of immature myeloid cells, which is characterized with poor outcomes. Despite tremendous advances in the treatment paradigm of AML in the past several decades, the cure and prognosis remain unfavorable. More effective treatments are therefore needed to improve the clinical outcomes. Among newly emerging immunotherapies, chimeric antigen receptor (CAR)-T cell immunotherapy is an exceedingly promising approach that has remarkably improved the overall survival for patients with AML. However, current CAR-T cell therapy for AML faces numerous significant challenges such as the identification of truly AML-specific surface antigens, the on-target/off-tumor toxicity, and the immunosuppressive microenvironment of AML. In order to conquer these limitations, novel strategies to advance CAR-T therapy are urgently needed. In this comprehensive review, we summarize the current status of immunotherapy, especially CAR-T cell therapy, highlight the outcomes of current trials and the limitations of CAR-T immunotherapy, hopefully to provide novel insights into the future directions of CAR-T cells in AML.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1572407/fullacute myeloid leukemiachimeric antigen receptor T cellimmunotherapyadoptive cell therapyimmunosuppressive microenvironment |
| spellingShingle | Yang Liu Wanting Wang Chaofan Wang Jun Deng Yu Hu Yu Hu Heng Mei Shanshan Luo Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia Frontiers in Immunology acute myeloid leukemia chimeric antigen receptor T cell immunotherapy adoptive cell therapy immunosuppressive microenvironment |
| title | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |
| title_full | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |
| title_fullStr | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |
| title_full_unstemmed | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |
| title_short | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |
| title_sort | recent advances of chimeric antigen receptor t cell therapy for acute myeloid leukemia |
| topic | acute myeloid leukemia chimeric antigen receptor T cell immunotherapy adoptive cell therapy immunosuppressive microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1572407/full |
| work_keys_str_mv | AT yangliu recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT wantingwang recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT chaofanwang recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT jundeng recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT yuhu recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT yuhu recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT hengmei recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia AT shanshanluo recentadvancesofchimericantigenreceptortcelltherapyforacutemyeloidleukemia |